# Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer

> **NCT05448001** · PHASE3 · COMPLETED · sponsor: **Onconic Therapeutics Inc.** · enrollment: 329 (actual)

## Conditions studied

- Gastric Ulcer

## Interventions

- **DRUG:** JP-1366 20mg
- **DRUG:** Lansoprazole 30mg

## Key facts

- **NCT ID:** NCT05448001
- **Lead sponsor:** Onconic Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-19
- **Primary completion:** 2024-07-10
- **Final completion:** 2024-07-19
- **Target enrollment:** 329 (ACTUAL)
- **Last updated:** 2024-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05448001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05448001, "Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05448001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*